Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Drug Delivery: Enteral Route01:18

Drug Delivery: Enteral Route

The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
Drugs in...
Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The genitourinary phenotype of COVID: a personal perspective.

International urology and nephrology·2026
Same author

Senescence-Driven Inflammation and Immune Dynamics in the Progression of Radiation Cystitis.

Cells·2026
Same author

Safety and Efficacy of LP-10 Liposomal Tacrolimus in Oral Lichen Planus: A Multicenter Phase 2 Trial.

Dermatology and therapy·2025
Same author

Advancing Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) Diagnosis: A Comparative Analysis of Machine Learning Methodologies.

Diagnostics (Basel, Switzerland)·2024
Same author

Rationale for the Use of Topical Calcineurin Inhibitors in the Management of Oral Lichen Planus and Mucosal Inflammatory Diseases.

Cureus·2024
Same author

Iltamiocel Autologous Cell Therapy for the Treatment of Female Stress Urinary Incontinence: A Double-Blind, Randomized, Stratified, Placebo-Controlled Trial.

Neurourology and urodynamics·2024

Related Experiment Video

Updated: May 15, 2026

In Vivo Luminal Measurement of Distension-Evoked Urothelial ATP Release in Rodents
09:17

In Vivo Luminal Measurement of Distension-Evoked Urothelial ATP Release in Rodents

Published on: September 7, 2022

Intravesical drug delivery for dysfunctional bladder.

Chun-Chien Hsu1, Yao-Chi Chuang, Michael B Chancellor

  • 1Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.

International Journal of Urology : Official Journal of the Japanese Urological Association
|January 23, 2013
PubMed
Summary

Intravesical therapy offers targeted bladder treatment with fewer side effects than oral medications. This review highlights advancements in local drug delivery for bladder conditions like interstitial cystitis and overactive bladder.

More Related Videos

Transurethral Instillation Procedure in Adult Male Mouse
04:01

Transurethral Instillation Procedure in Adult Male Mouse

Published on: November 2, 2017

Related Experiment Videos

Last Updated: May 15, 2026

In Vivo Luminal Measurement of Distension-Evoked Urothelial ATP Release in Rodents
09:17

In Vivo Luminal Measurement of Distension-Evoked Urothelial ATP Release in Rodents

Published on: September 7, 2022

Transurethral Instillation Procedure in Adult Male Mouse
04:01

Transurethral Instillation Procedure in Adult Male Mouse

Published on: November 2, 2017

Area of Science:

  • Urology
  • Pharmacology
  • Biotechnology

Background:

  • Dysfunctional bladder conditions, including interstitial cystitis/bladder pain syndrome, overactive bladder, and hemorrhagic cystitis, are increasingly treated with local organ-specific therapies.
  • Intravesical therapy, involving direct administration into the bladder, offers advantages over systemic oral therapy, such as higher local drug concentrations and reduced systemic toxicity.
  • Advancements in drug delivery platforms, particularly lipid-based systems, are enhancing the efficacy and safety of intravesical treatments.

Purpose of the Study:

  • To review the current status of intravesical therapy for various dysfunctional bladder conditions.
  • To emphasize the role of novel drug delivery systems, especially lipid-based platforms, in improving intravesical treatment outcomes.
  • To discuss the potential of intravesical delivery for biotechnological products like neurotoxins and immunosuppressive agents.

Main Methods:

  • Literature review focusing on intravesical drug delivery for bladder dysfunction.
  • Analysis of studies on interstitial cystitis/bladder pain syndrome, overactive bladder, and hemorrhagic cystitis treatments.
  • Examination of novel drug delivery platforms, including liposomes, for intravesical administration.

Main Results:

  • Intravesical therapy demonstrates variable efficacy and safety profiles for treating interstitial cystitis/bladder pain syndrome, overactive bladder, and hemorrhagic cystitis.
  • Lipid-based drug delivery systems show promise for enhancing the effectiveness of intravesical treatments for lower urinary tract symptoms.
  • Biotechnological products delivered intravesically are emerging as potential therapeutic options.

Conclusions:

  • Intravesical therapy is a valuable approach for managing dysfunctional bladder conditions, offering localized treatment benefits.
  • Novel drug delivery platforms, particularly lipid-based ones, are crucial for optimizing intravesical therapy efficacy and minimizing systemic side effects.
  • Continued research into intravesical drug delivery holds significant potential for improving patient outcomes in urological disorders.